#France #Pierre Fabre #Castres #cetuximab #BRAFTOVI

Pierre Fabre Laboratories Receives Positive CHMP Opinion for BRAFTOVI®

Pierre Fabre Laboratories, based in France, has announced a significant breakthrough in oncology with the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation is for the drug BRAFTOVI® (encorafenib), which when combined with Cetuximab and FOLFOX (a regimen of fluorouracil, leucovorin, and oxaliplatin), is aimed at treating adult patients suffering from BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Background of the CHMP Recommendation

The CHMP's endorsement is founded on the promising results gathered from the Phase-3 BREAKWATER study, which demonstrated that BRAFTOVI® in conjunction with Cetuximab and mFOLFOX6 presents a statistically significant improvement in patient outcomes. Specifically, the combination therapy showcased a remarkable enhancement in both overall response rates (ORR) and progression-free survival (PFS). The study revealed a 51% reduction in the risk of death when compared to chemotherapy options, with or without the addition of Bevacizumab.

Efficacy Results from the BREAKWATER Study

The BREAKWATER trial evaluated the effectiveness and safety of the BRAFTOVI® regimen in previously untreated patients who have the BRAFV600E mutation in their metastatic colorectal cancer. Findings indicated a meaningful increase in median PFS, highlighting an impressive 12.8 months compared to 7.1 months seen with standard chemotherapy treatments. Such data underlines the potential of BRAFTOVI® as a leading-targeted therapy option for this specific patient group.

Implications of Approval

If the European Commission grants marketing authorization based on the CHMP's positive opinion, BRAFTOVI® will become the first and only approved targeted therapy designed specifically for first-line treatment in adults with BRAFV600E-mutated metastatic colorectal cancer within the European Union. This would greatly alter the therapeutic landscape for mCRC, offering a more effective treatment option to those afflicted with this aggressive form of cancer.

Eric Ducournau, the Chief Executive Officer of Pierre Fabre Laboratories, expressed that this positive recommendation represents an important step towards an innovative, targeted treatment solution for patients suffering from BRAFV600E mutated metastatic colorectal cancer. He reaffirmed the company’s commitment to pushing meaningful oncology innovations and collaborating closely with the medical community to address substantial unmet needs in cancer care.

This milestone not only signifies progress in the fight against this challenging disease but also highlights the ongoing efforts of pharmaceutical companies to develop targeted therapies that are both effective and reliable.

Conclusion

With the European Commission's decision anticipated later this year, the industry is eager to see how this approval could reshape treatment protocols and improve patient outcomes for those battling BRAFV600E-mutated mCRC. As Pierre Fabre Laboratories awaits the final ruling, the positive findings from the BREAKWATER study serve as a beacon of hope in the oncology sector, promising a nuanced approach to cancer treatment focusing on genetic mutations that dictate patient care paths.